Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer.
The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent-based chemotherapy for solid tumors. We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia. The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade. Monitoring of the long-term outcome of paclitaxel- and platinum-based regimens is warranted, particularly with regard to monitoring the development of secondary MDS and/or AML. The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.
See
H T
HT
Department of Gynecological Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Thomas
D A
DA
Bueso-Ramos
C
C
Kavanagh
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001132:Arm; D002066:Busulfan / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007890:Leiomyosarcoma / Q000601:surgery; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced* / Q000628:therapy; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D009375:Neoplasms, Glandular and Epithelial / Q000556:secondary / Q000628:therapy*; D016609:Neoplasms, Second Primary; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012086:Reoperation; D033581:Stem Cell Transplantation; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
D003561:Cytarabine; D016190:Carboplatin; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine; D017239:Paclitaxel; D015255:Idarubicin